Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab in Relapsed/Refractory Classical Hodgkin's Lymphoma
NCT03114683Phase 2Completed
- Sponsor
- Innovent Biologics
- Start
- Mar 2017
- Primary completion
- Sep 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in classical Hodgkin lymphoma (cHL), sponsored by Innovent Biologics. Started Mar 2017; status: completed.
02
Drugs
sintilimab
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT03114683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03114683.